Category Archives: Immunology

How a Few Drops of Blood Led to An Immunology Breakthrough – Drug Discovery & Development

Scientists from the Research Institute of the McGill University Health Centre (RI-MUHC) may have cracked the code to understanding the function of special cells called regulatory T Cells. Treg cells, as they are often known, control and regulate our immune system to prevent excessive reactions. The findings, published in Science Immunology, could have a major impact in our understanding and treatment of all autoimmune diseases and most chronic inflammatory diseases such as arthritis, Crohns disease as well as broader conditions such as asthma, allergies and cancer.

Researchers made this discovery by investigating a rare human mutation in a gene called FOXP3. Although the importance of the FOXP3 gene in the proper function of Treg cells has been well documented, its mechanisms were still not fully understood by scientists.

We discovered that this mutation in the FOXP3 gene affects the Treg cells ability to dampen the immune response, which results in the immune system overreacting and causing inflammation, explains the studys lead author, Dr. Ciriaco Piccirillo, immunologist and senior scientist in the Infectious Diseases and Immunity in the Global Health Program at the RI-MUHC, and a professor of Immunology at McGill University. This discovery gives us key insights on how Treg cells are born and how they can be regulated.

Thanks to an international collaboration and cutting-edge technology from the Immunophenotyping Platform at the RI-MUHC, the team was able to make their discovery using only a few drops of blood from a five-week-old newborn boy who died in 2009 from a rare and often fatal inherited genetic immune disorder called IPEX. In the past 40 years, fewer than 200 cases of IPEX have been identified worldwide. Over 60 different mutations of the FOXP3 gene are known to cause IPEX and believed to result in non-functional Treg Cells.

What was unique about this case of IPEX was that the patients Treg cells were fully functional apart from one crucial element: its ability to shut down the inflammatory response, says Dr. Piccirillo.

Understanding this specific mutation has allowed us to shed light on how many milder forms of chronic inflammatory diseases or autoimmune diseases could be linked to alterations in FOXP3 functions, adds the studys first author, Khalid Bin Dhuban, a postdoctoral fellow in Dr. Piccirillos laboratory.

From fundamental biology to clinical treatment

Dr. Piccirillo and his colleagues have already developed a molecule that could restore the Treg cells' ability to control the immune system for patients with the same rare mutation. The drug has been tested in animal models and the researchers are hopeful they can also develop similar drugs that will apply for other conditions where Treg cells are known to be slightly defective such as arthritis, type I diabetes, multiple sclerosis and lupus.

"Currently, we have to shut down the whole immune system with aggressive suppressive therapies in various autoimmune and inflammatory diseases," explains Dr. Piccirillo. Our goal is to increase the activity of these Treg cells in certain settings, such as autoimmune diseases, but we want to turn it down in other settings, such as cancer. With this discovery, we are taking a big step in the right direction.

Dr. CiriacoPiccirillo is also the director of theCentre of Excellence in Translational Immunology (CETI), a newly established research coalition based at the Research Institute of the MUHC that fosters linkages among biomedical investigators and clinicians for interdisciplinary immunology research focused on the understanding and treatment of immune-based diseases.

View post:
How a Few Drops of Blood Led to An Immunology Breakthrough - Drug Discovery & Development

How a few drops of blood led to a breakthrough in immunology – Medical Xpress

July 5, 2017 The image shows a lymph node in which we see normal T cells (in red) and Treg cells regulated by the FOXP3 gene (in green). Lymph nodes are small glands that are part of the lymph system which is important for body's defense system against diseases. Technique used: Confocal microscopy Credit: Ciriaco Piccirillo, Research Institute of the McGill University Health Centre

Scientists from the Research Institute of the McGill University Health Centre (RI-MUHC) may have cracked the code to understanding the function of special cells called regulatory T Cells. Treg cells, as they are often known, control and regulate our immune system to prevent excessive reactions. The findings, published in Science Immunology, could have a major impact in our understanding and treatment of all autoimmune diseases and most chronic inflammatory diseases such as arthritis, Crohn's disease as well as broader conditions such as asthma, allergies and cancer.

Researchers made this discovery by investigating a rare human mutation in a gene called FOXP3. Although the importance of the FOXP3 gene in the proper function of Treg cells has been well documented, its mechanisms were still not fully understood by scientists.

"We discovered that this mutation in the FOXP3 gene affects the Treg cell's ability to dampen the immune response, which results in the immune system overreacting and causing inflammation," explains the study's lead author, Dr. Ciriaco Piccirillo, immunologist and senior scientist in the Infectious Diseases and Immunity in the Global Health Program at the RI-MUHC, and a professor of Immunology at McGill University. "This discovery gives us key insights on how Treg cells are born and how they can be regulated."

Thanks to an international collaboration and cutting-edge technology from the Immunophenotyping Platform at the RI-MUHC, the team was able to make their discovery using only a few drops of blood from a five-week-old newborn boy who died in 2009 from a rare and often fatal inherited genetic immune disorder called IPEX. In the past 40 years, fewer than 200 cases of IPEX have been identified worldwide. Over 60 different mutations of the FOXP3 gene are known to cause IPEX and believed to result in non-functional Treg Cells.

"What was unique about this case of IPEX was that the patient's Treg cells were fully functional apart from one crucial element: its ability to shut down the inflammatory response," says Dr. Piccirillo.

"Understanding this specific mutation has allowed us to shed light on how many milder forms of chronic inflammatory diseases or autoimmune diseases could be linked to alterations in FOXP3 functions," adds the study's first author, Khalid Bin Dhuban, a postdoctoral fellow in Dr. Piccirillo's laboratory.

From fundamental biology to clinical treatment

Dr. Piccirillo and his colleagues have already developed a molecule that could restore the Treg cells' ability to control the immune system for patients with the same rare mutation. The drug has been tested in animal models and the researchers are hopeful they can also develop similar drugs that will apply for other conditions where Treg cells are known to be slightly defective such as arthritis, type I diabetes, multiple sclerosis and lupus.

"Currently, we have to shut down the whole immune system with aggressive suppressive therapies in various autoimmune and inflammatory diseases," explains Dr. Piccirillo. Our goal is to increase the activity of these Treg cells in certain settings, such as autoimmune diseases, but we want to turn it down in other settings, such as cancer. With this discovery, we are taking a big step in the right direction."

Dr. Ciriaco Piccirillo is also the director of the Centre of Excellence in Translational Immunology (CETI), a newly established research coalition based at the Research Institute of the MUHC that fosters linkages among biomedical investigators and clinicians for interdisciplinary immunology research focused on the understanding and treatment of immune-based diseases.

Explore further: Preventing too much immunity

More information: Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions, Science Immunology 16 Jun 2017: Vol. 2, Issue 12, eaai9297 , DOI: 10.1126/sciimmunol.aai9297 , http://immunology.sciencemag.org/content/2/12/eaai9297

An immune-related protein deployed between neighboring cells in Drosophila plays an essential role in the cell degradation process known as autophagy, according to new research by Eric H. Baehrecke, PhD, at UMass Medical ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Continued here:
How a few drops of blood led to a breakthrough in immunology - Medical Xpress

Sun Pharma agrees manufacturing deal for immunology candidate – The Pharma Letter (registration)

India's largest drugmaker Sun Pharmaceutical has entered into a manufacturing agreement with South Koreas

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

BiotechnologyDealsImmunologicalsIndiaProductionSamsung BioLogicsSouth KoreaSun Pharmaceutical Industriestildrakizumab

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

Read more:
Sun Pharma agrees manufacturing deal for immunology candidate - The Pharma Letter (registration)

Immunology, one cell at a time : Nature News & Comment – Nature.com

Amir Giladi & Ido Amit

Single-cell genomics can identify unique immune cells (red) involved in Alzheimer's disease.

For more than a century, scientists have tried to characterize the different functions of the 10 trillion to 50 trillion cells of the human body from neurons, which can reach 1 metre in length, to red blood cells, which are around 8 micrometres wide. Such efforts have helped to identify important cell types and pathways that are involved in human physiology and pathology.

But it has become apparent that the research tools of the past few decades fail to capture the full complexity of cell diversity and function. (These tools include fluorescent tags fused to antibodies that bind to specific proteins on the surfaces of cells, known as cell-surface markers, and sequencing in bulk of the RNA or DNA of thousands of seemingly identical cells.) This failure is partly because many cells with completely different functions have similar shapes or produce the same markers.

Single-cell genomics is transforming the ability of biologists to characterize cells. The new techniques that have emerged aim to capture individual cells and determine the sequences of the molecules of RNA and DNA that they contain. The shift in approach is akin to the change in how cells and molecules could be viewed during the 1980s, following advances in microscopy and the tagging and sorting of cells.

In the past five years, several groups of biologists, including our own laboratory, have gone from measuring the expression of a few genes in a handful of cells to surveying thousands of genes in hundreds of thousands of cells from intact tissues. New cell types1, 2, cellular states and pathways are being uncovered regularly as a result.

Our lab was one of the first to study the immune system using single-cell genomics. The tools are particularly suited to this task because the heterogeneity and plasticity of cells are integral to how the immune system works the nature of each agent that could attack the body being impossible to know ahead of time.

Exploiting single-cell genomics fully will require scientists and clinicians to make experimental and analytical adjustments. In particular, we must be ready to jettison assumptions about cell types and cellular states, and to rebuild representations of cellular networks.

The cells of the immune system, which patrol the blood and dwell in tissues, have many functions. They protect the body from pathogens and cancer, and orchestrate metabolism and the formation of organs. They are involved in almost every activity that regulates the bodys internal environment, from the development and remodelling of tissues to the clearance of dying cells and debris. So their dysfunction can cause many problems. For instance, deregulated immune cells can attack healthy cells and cause autoimmune conditions such as lupus, type 1 diabetes or multiple sclerosis.

A first step towards harnessing the immune system for therapeutic use is to characterize the types of cell that occupy a specific area (such as the surroundings of a tumour). Another is to map the unique processes and pathways that the cells are involved in, the genes they express and the cells interactions and responses to environmental cues. Over the past 40 years, meticulous approaches based on genetic labelling have enabled researchers to identify dozens of types and functions of immune cells. For example, the use of antibodies fused to fluorescent tags that bind to and flag specific cell-surface markers established the basic taxonomy of immune cells including several types of T cells, B cells, monocytes and granulocytes. Such studies also kick-started the search for treatments known as immunotherapies, which harness the body's natural defences to fight disease.

Increasingly, however, these techniques hint that the world of immune cells is more complex than current categories allow. Immune cells seem to change their functions depending on their surroundings. For instance, macrophages (as identified by their cell-surface markers) might have one function in the gut yet a completely different one in the brain3. Also, molecular markers cannot fully describe the functional diversity of cells in different immune contexts. For example, a group of immune cells that suppresses the immune response around tumours (myeloid-derived suppressor cells) has been shown to express markers from both monocytes and granulocytes4.

In short, conventional methods based on populations of cells are proving too blunt a tool with which to tease apart complex immune assemblies5.

In the past five years, technologies for capturing single cells have improved dramatically. Some approaches rely on placing cells inside miniature vessels, one at a time; others capture individual cells inside droplets of oil. Meanwhile, bioinformaticians have built algorithms for representing multidimensional data, identifying distinct cellular states and modelling the transitions between such states6.

Thanks to these developments, researchers can now capture hundreds of thousands (or even millions) of cells and accurately measure the DNA, RNA or protein content of each (see Scale up). Gene-editing tools such as the CRISPRCas9 system can be used to introduce a specific mutation into the genome of one cell, and then a different alteration into the next7. Thus, the function of dozens of genes can be inferred from just one experiment by reading the resulting RNA barcode in parallel with the single-cell genetic information.

With such measurements, researchers can potentially record the functional states of many cells at once8. They can also probe the ancestry of individual cells9 or identify mutations in a particular cells DNA, as well as track communication between cells. In other words, single-cell genomics allows researchers to build an accurate representation of the entire make-up of a tissue10, such as a specific organ or a tumour, or of a multicellular process such as the immune systems response to an infection. Importantly, it enables them to do this without making prior assumptions based on, for instance, the participating cell types and their characteristics.

About 20 labs worldwide have fully embraced single-cell genomics, and even more are trying out the approach. In the past few years, numerous papers have been published that describe new types of immune cell and previously unknown pathways involved in various conditions.

For instance, 15 subtypes of innate lymphoid cell, which are similar to T cells but do not express the T-cell receptor, have been identified in the gut11. Different progenitors of immune-cell lineages have been uncovered in the bone marrow12. Specific types of immune cell have been associated with particular stages of tumour growth13, 14. And various types of microglial cell have been identified in the brain during development.

Last month, our lab reported the discovery of a new type of immune cell in the brain, disease-associated microglia (DAM)15. Our experiments indicate that DAM break down dead cells and protein aggregates called plaques in the brains of mice engineered to express mutated proteins associated with Alzheimers disease.

More than a decade of population-based assays, including cell sorting using specific cell-surface markers and bulk RNA sequencing, had failed to flag these cells. Only by individually sequencing the RNA of each of the immune cells in a sample of brain were we able to find a rare subpopulation of microglia that may open up fresh approaches to treating Alzheimers disease.

It is early days for single-cell genomics. But already, a number of important lessons can be learnt from the experiences of our lab and those of others.

First, it is clear that many of the current categories of immune cells, such as T cells or monocytes, encompass heterogeneous populations. To probe cellular complexity, researchers must therefore cast their nets wide, and try to collect all immune cells within a tissue or region of interest. This is a very different approach from that used with methods based on cell-surface markers, which aim to obtain as pure a sample as possible.

Second, success will depend, in part, on the extent to which researchers preserve the states of cells and the original composition of a tissue. Cell stress or death should be minimized to ensure that tissue preparation does not favour specific cell types. (Some are more sensitive to heat stress, for example, than others.)

Single-cell genomics will soon be commonplace in basic and applied immunology research.

Third, bioinformaticians will need to develop scalable and robust algorithms to cope with greater numbers of cells, conflicting or overlapping programs of gene expression and fleeting developmental stages.

Fourth, after researchers have characterized all of the immune cells in a sample, they will need to find molecular markers that can be used to either enrich or deplete certain cell types in further samples. Tissues comprise trillions of cells with myriad molecular characteristics and functions, and the types or states of these cells may vary in abundance by many orders of magnitude. For instance, in the brains of healthy mice, our newly identified population of DAM makes up less than 0.01% of cells15. Thus, repeated unbiased sampling to characterize rare populations will keep on accumulating cells that are not those of interest.

Other experimental, computational and statistical approaches can help to overcome this problem. Importantly, once a rare population of cells is identified using single-cell genomics, they can be purified and experiments conducted only on them. In our recent study, for instance, we used cell-surface markers to isolate DAM and then assessed their role in Alzheimers disease using various techniques, including fluorescent labelling.

A fifth lesson regards a considerable drawback of current single-cell technologies. They capture snapshots of dynamic systems, in which cells are devoid of important context spatial, temporal, clonal and epigenetic. Without knowing where a profiled cell came from, who its neighbours were or what it developed from, it is hard to model complex processes such as tissue formation or a tumours interaction with nearby immune cells.

One way around this problem might be to combine several layers of information from the same cell. Genetic fluorescent labelling, for instance, can be used to track changes in the state of a cell over time or to find exactly where it is in a tissue.

Ultimately, textbook definitions and long-held beliefs about cellular identities, such as the distinction between cell type and cell state, will almost certainly need to be rethought. Some classifications of subgroups based on extra markers may prove helpful in the short term, but can quickly become unwieldy. For example, instead of being able to refer to T-helper (TH) cells, researchers must now refer to one of about a dozen subcategories, including TH1 cells and TH2 cells16. And such an approach may continue to overlook the true functional complexity of the immune ecosystem.

A more workable solution may be for researchers to replace rigid classifications with assemblies of gene-expression programs (see Genetic microscope). These elaborate gene maps could represent all cell types and states, including those from different physiological and pathological contexts. Such maps would allow biologists to define cells not just by one fate, lineage or function, but by the combination of all of these. It would also allow these functional entities to be compared across organisms.

Claire Welsh/Nature

Single-cell genomics will soon be commonplace in basic and applied immunology research. This is thanks to efforts to make the tools affordable, standardized and accessible to academia, the biotech industry and the clinic. We predict that, within a decade, blood samples or biopsies will be routinely sent for single-cell genomic analysis, and the entire immune composition of patients analysed and compared with all known healthy and diseased states.

Also likely to undergo rapid transformation is our understanding of tumours and tumour stem cells, processes such as neuronal development, metabolic disorders and neural function.

Almost every scientific breakthrough has originated from a new measurement or observation that enabled scientists to come up with new hypotheses and merge them into unifying theories. Robert Hookes observation of cells as units of multicellular organisms, James Watson and Francis Cricks discovery of the 3D structure of DNA and Edwin Hubbles detection of galaxies beyond the Milky Way could not have been achieved without new ways of seeing.

The molecular microscope of single-cell genomics is already adding to our knowledge of cell types and gene pathways. But for single-cell genomics to tell us something truly new about the blueprint of humans, we will have to address how individual cells communicate to achieve shared goals.

Here is the original post:
Immunology, one cell at a time : Nature News & Comment - Nature.com

Sansum Allergy/Immunology Department Moving – Noozhawk

Posted on June 30, 2017 | 9:00 a.m.

On Monday, July 17, the Sansum Clinic Allergy & Immunology Department will move to 51 Hitchcock Way in Santa Barbara. The new location is adjacent to Sansum's Pediatrics and Adolescent Medicine Department.

The Allergy & Immunology Department offers comprehensive care for children and adults with allergic and immunologic disorders, including the following:

Immunotherapy (allergy shots); pediatric and adult pulmonary testing; allergy blood and skin testing; patch skin testing; oral challenge testing; drug testing; lab and x-ray services.

The entrance to the new department is on Hitchcock Way, across the street from the YMCA and accessible from Highway 101 or State Street. The practice will be on the first floor.

To learn more about Sansum Clinic, visit http://www.sansumclinic.org.

Elizabeth Baker for Sansum Clinic.

Visit link:
Sansum Allergy/Immunology Department Moving - Noozhawk

Merck’s Immunology and Cardiovascular Franchise in 1Q17 – Market … – Market Realist

Merck & Co.s Recent Developments and Valuations PART 10 OF 11

Merck & Co.s (MRK) Immunology franchise includes Remicade and Simponi. Remicade is one of the top-selling drugs for the treatment of inflammatory disorders, while Simponi is a once-monthly subcutaneous treatment. Both drugs reported a decline in revenues during 1Q17.

Remicades revenues fell ~34% to $229 million in 1Q17, compared to $349 million for 1Q16. This decline was due to the entry of generic competition and biosimilars following the loss of exclusivity of Remicade in the European markets in February 2015. Merck expects Remicades revenues to continue their declines, as new patients prefer biosimilars over Remicade.

While Merck has the marketing rights for Remicade in the European markets, Johnson & Johnson (JNJ) holds marketing rights of Remicade in several countries outside Europe.

Simponis revenues fell to $184 million in 1Q17, compared to $188 million in 1Q16.

Mercks Cardiovascular franchise includes the blockbuster drugs Zetia and Vytorin. These drugs are used for lowering the LDL cholesterol levels in the blood of patients with a high risk of cardiovascular disease.

The combined revenues for Zetia and Vytorin fell 35% to $575 million in 1Q17, compared to $889 million in 1Q16. Zetia competes with AbbVies (ABBV) Niaspan and Pfizers (PFE) Lipitor.

To divest company-specific risks, investors can consider the iShares Core High Dividend ETF (HDV), which holds ~3.5% of its total assets in Merck. HDV also holds 4.9% in Pfizer (PFE) and 1.5% in Eli Lilly & Co. (LLY).

Read the original:
Merck's Immunology and Cardiovascular Franchise in 1Q17 - Market ... - Market Realist

Immunology Professor and FoodCloud Co-Founder Represent Trinity in List of Powerful Irish Women – The University Times

Dominic McGrathDeputy Editor

FoodCloud

A Trinity professor and a Launchbox graduate have been named in a new list of Irelands top 25 most powerful women, alongside some of the biggest names in Irish society.

Prof Lydia Lynch, who is an associate professor of immunology in Trinity, was named in the Womens Executive Networks list of Irelands most powerful women. She received the award alongside Launchbox graduate and FoodCloud co-founder Iseult Ward.

The annual list, which has been published since 2012, selects the most influential and successful women in Ireland and both Lynch and Ward appear alongside some of the biggest names in Irish media, finance and law. Womens Executive Network is an international organisation that supports women with mentoring and networking and the annual list has long been used to recognise the success of Irish women across various fields.

Lynch, in a press statement, said she was proud to receive this award as a woman and mother in science.

I hope it shows that if I can do it, others can too. It doesnt matter what kind of background, gender or family youre from. Lynchs research focuses on the role that our immune systems have in regulating metabolism, with the aim being to understand how our immune systems could be used to target cancer.

Cancer immunotherapy is at an exciting time and the more we are finding out about how to reinvigorate the immune system to attack cancer, the better the chances are of it working in more people, she said.

Ward, whose company is often touted as one of the great successes of Trinitys summer-long accelerator programme, only began FoodCloud in 2014 but the company has already established itself as an important social enterprise business. The company helps businesses redistribute surplus or short-dated food to charities across Ireland. Alison Treacy, the manager of Launchbox, said in a press statement: Iseult was part of our 2014 programme, and since then has been a valuable supporter of and ambassador for LaunchBox and its student entrepreneurs. We are so pleased and proud to have been able to support her and FoodCloud in the early days of the company.

This year, Launchbox launched a campaign to encourage more women to get involved in entrepreneurship.

Other names on the list include everyone from Olympian Annalise Murphy; the Director General of RT, Dee Forbes; the CEO of Leicester City Football Club, Susan Whelan; and Justice Siofra OLeary, a judge in the European Court of Human Rights.

Both Lynch and Ward received their award in the trailblazers category.

In a press statement, Sherri Stevens, CEO of the Womens Executive Network, said: Our winners include an Olympic Silver Medallist, a Michelin-starred chef, many CEOs and entrepreneurs, a European Court of Human Rights Justice and a professor whose research is changing our understanding of obesity and immunity.

All 25 are trailblazers and role models for the generations who will follow, she added.

Go here to see the original:
Immunology Professor and FoodCloud Co-Founder Represent Trinity in List of Powerful Irish Women - The University Times

What’s in Celgene’s Immunology and Inflammation Clinical Pipeline? – Market Realist

These Drugs Could Drive Celgene's Growth in 2017 PART 5 OF 8

Celgenes (CELG) Ozanimod is a selective S1P 1 and S1P 5 modulator. Data from phase three trial SUNBEAMhas demonstrated the efficacy and safety of Ozanimod as a treatment option for patients suffering from relapsing multiple sclerosis. In May 2017, Celgene (CELG) announced its success in the second pivotal (RADIANCE) phase three trial. The RADIANCE trial aimed to evaluate the safety and efficacy of Ozanimod in relapsing multiple sclerosis patients. The primary endpoint of the RADIANCE study was to reduce the annualized relapse rate (or ARR). Ozanimod demonstrated a significant reduction in ARR.

The company expects to start several pivotal trials in 2017. After the success of ozanimod in the STEPSTONE phase two trial, the company may begin phase three trials for the evaluation of the drug as a treatment for Crohns disease.

The above table indicates Celgenes different ongoing trials in inflammation, immunology, and cellular therapies.

After the success of Otezla in the marketplace, Celgene has started various other trials on the drug for label expansion in areas such as atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.

Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept. The drug is being investigated in phase three trials, MEDALIST and BELIEVE, to evaluate its efficacy as a therapy option for patients suffering from myelodysplastic syndromes and beta-thalassemia, respectively.

Celgene has started a pivotal trial to study investigational therapy GED-301 for Crohns disease, while the phase two trial for the drug in ulcerative colitis indications is expected to conclude by mid-2017. The company anticipates that ozanimod and GED-301 may turn out to be future blockbuster drugs. Celgenes revenue growth may boost the share prices of the Vanguard Health Care ETF (VHT). Celgene makes up about 2.7% of VHTs total portfolio holdings.

Celgenes peers in the inflammation and immunology drug market include Johnson & Johnson (JNJ), Amgen (AMGN), AbbVie (ABBV), and Novartis.

Read the original:
What's in Celgene's Immunology and Inflammation Clinical Pipeline? - Market Realist

Global Immunology Drugs Market 2017-2022 – mAbs Market Expected to Experience Continued Growth from $57.7 … – PR Newswire (press release)

The report Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease.

Although the patents for many of these mAbs have either already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $57.7 billion in 2015 to $75.4 billion in 2022, at a compound annual growth rate (CAGR) of 3.88%.

This is due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline. There is a large pharmaceutical pipeline for immunology, consisting of 2,054 products in active development. The majority of pipeline products (73%) are in the early stages of development, at either the Preclinical or Discovery stages, but 96 (5%) are in Phase III.

The key market players, namely AbbVie, Johnson & Johnson, Roche, Amgen and Pfizer, are forecast to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries - especially that of adalimumab, marketed by AbbVie, and Remicade, marketed by Johnson & Johnson - will affect these companies directly.

Key Topics Covered:

1 Introduction

2 Key Marketed Products

3 Pipeline Landscape Assessment

4 Multi-scenario Market Forecast to 2022

5 Company Analysis and Positioning

6 Strategic Consolidations

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/kv7xk5/global_immunology

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-immunology-drugs-market-2017-2022---mabs-market-expected-to-experience-continued-growth-from-577-billion-in-2015-to-754-billion-in-2022-at-a-cagr-of-388---research-and-markets-300477452.html

SOURCE Research and Markets

http://www.researchandmarkets.com

More:
Global Immunology Drugs Market 2017-2022 - mAbs Market Expected to Experience Continued Growth from $57.7 ... - PR Newswire (press release)

In Brief Immunology expert Robert Ferris named director of UPMC Hillman Cancer Center – The Cancer Letter Publications

publication date: Jun. 16, 2017

In Brief Immunology expert Robert Ferris named director of UPMC Hillman Cancer Center

Robert Ferris, an expert in immunotherapy and specialist in head and neck cancer, was named director of UPMC Hillman Cancer Center.

Starting July 1, Ferris, a 15-year veteran of the UPMC Hillman Cancer Center, will have overall responsibility for all aspects of cancer research and education at the NCI-designated comprehensive cancer center. His appointment follows a nationwide search after the departure of Nancy Davidson (The Cancer Letter, Oct. 14, 2016).

Ferris serves as chief of the Division of Head and Neck Oncologic Surgery in the departments of Otolaryngology and Immunology. He also serves as co-leader of the Cancer Immunology Program and most recently was appointed associate director for translational research and co-director of the Tumor Microenvironment Center.

The development and implementation of immunotherapy to treat head and neck tumors has been the primary research focus of the Ferris laboratory. The goals of this research are to boost the bodys immune response against cancer. More recently, his work focuses on how immune cells in the tumor microenvironment influence cancer progression and can be harnessed to advance treatment.

Ferris is co-chair of the NCI Steering Committee for Head and Neck Cancer, at-large director of the Society for Immunotherapy of Cancer, senior examiner of the American Board of Otolaryngology, and chair of the NCI Tumor Microenvironment Study Continue reading Immunology expert Robert Ferris named director of UPMC Hillman Cancer Center

Originally posted here:
In Brief Immunology expert Robert Ferris named director of UPMC Hillman Cancer Center - The Cancer Letter Publications